Altimmune (ALT – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The company’s shares ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT stock is a Buy.

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune (ALT – Research Report) on February 28 and set a price target of $25.00.

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Stock analysts at B. Riley increased their FY2025 earnings estimates for Altimmune in a research note issued on Friday, February 28th. B.

NASDAQ:ALT opened at $6.65 on Friday. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.05. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...